B.Riley lowers Hyperfine stock price target on valuation adjustment
B.Riley lowered its price target on Hyperfine Inc. (HYPR) to $1.40 from $1.60, maintaining a Buy rating. Q3 2026 revenue was $6.0M, beating estimates, with a loss per share of $0.06. Revenue grew 73% YoY, and gross margin expanded to 57%. The company reaffirmed fiscal 2026 guidance and extended its cash runway into 2028.
How this was made
The 30-second read
Why it matters
Earnings beat and cash strength may attract value‑oriented traders, while the target cut could trigger short‑covering.
Market read
Primary earnings disclosure for a micro‑cap; modest trading relevance.
What to watch
Potential future contracts or FDA approvals could further boost revenue beyond guidance.
Background
Hyperfine is a micro‑cap medical imaging company reporting its Q3 FY2026 results and an analyst price‑target adjustment.
Ticker impact
B.Riley lowered HYPR's price target to $1.40 and reported Q3 FY2026 results with revenue of $6.0M and a loss per share of $0.06.
likely modest upside as the market prices in the earnings beat and lower loss, tempered by the target reduction.
The earnings beat and cash runway extension are positive, but the lower price target signals caution.
Market effects
Improves outlook for the medical imaging niche as margins expand.
Limited to U.S. micro‑cap investors.
Low; impact confined to HYPR shareholders.
Counterpoint
Target cut may be overly cautious given strong cash position and margin expansion.
Key entities
- companyHyperfine Inc.
Medical imaging device maker (NASDAQ:HYPR).
- analystB.Riley
Equity research analyst who lowered the price target.


